12/23
10:22 am
sage
Sage Therapeutics (SAGE) Surges 12.2%: Is This an Indication of Further Gains? [Yahoo! Finance]
Low
Report
Sage Therapeutics (SAGE) Surges 12.2%: Is This an Indication of Further Gains? [Yahoo! Finance]
12/16
08:30 am
sage
Sage Therapeutics, Inc. (NASDAQ: SAGE) had its price target lowered by analysts at Stifel Nicolaus from $10.00 to $6.00. They now have a "hold" rating on the stock.
Low
Report
Sage Therapeutics, Inc. (NASDAQ: SAGE) had its price target lowered by analysts at Stifel Nicolaus from $10.00 to $6.00. They now have a "hold" rating on the stock.
12/10
10:05 am
sage
Yahoo Finance [Yahoo! Finance]
Low
Report
Yahoo Finance [Yahoo! Finance]
11/26
07:00 am
sage
Sage Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference
Medium
Report
Sage Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference
11/21
01:30 pm
sage
Biotech Stock Roundup: SAGE, INCY Suffer Setbacks, JAZZ Wins Oncology Drug Approval & More [Yahoo! Finance]
Low
Report
Biotech Stock Roundup: SAGE, INCY Suffer Setbacks, JAZZ Wins Oncology Drug Approval & More [Yahoo! Finance]
11/21
12:32 pm
sage
SAGE's Dalzanemdor Fails to Meet Goal in Huntington's Disease Study [Yahoo! Finance]
Low
Report
SAGE's Dalzanemdor Fails to Meet Goal in Huntington's Disease Study [Yahoo! Finance]
11/21
12:24 pm
sage
Sage Therapeutics, Inc. (NASDAQ: SAGE) had its price target lowered by analysts at TD Cowen from $10.00 to $9.00. They now have a "hold" rating on the stock.
Low
Report
Sage Therapeutics, Inc. (NASDAQ: SAGE) had its price target lowered by analysts at TD Cowen from $10.00 to $9.00. They now have a "hold" rating on the stock.
11/21
08:05 am
sage
Sage Therapeutics, Inc. (NASDAQ: SAGE) was upgraded by analysts at Royal Bank of Canada from an "underperform" rating to a "sector perform" rating. They now have a $4.00 price target on the stock.
Low
Report
Sage Therapeutics, Inc. (NASDAQ: SAGE) was upgraded by analysts at Royal Bank of Canada from an "underperform" rating to a "sector perform" rating. They now have a $4.00 price target on the stock.
11/20
01:16 pm
sage
Sage Therapeutics, Inc. (NASDAQ: SAGE) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $14.00 price target on the stock.
Low
Report
Sage Therapeutics, Inc. (NASDAQ: SAGE) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $14.00 price target on the stock.
11/20
10:50 am
sage
After Failed Alzheimer's Study, Sage Therapeutics' Dalzanemdor Flunks Another Study In Patients With Inherited Brain Disorder [Yahoo! Finance]
Low
Report
After Failed Alzheimer's Study, Sage Therapeutics' Dalzanemdor Flunks Another Study In Patients With Inherited Brain Disorder [Yahoo! Finance]
11/20
08:32 am
sage
Sage Therapeutics, Inc. (NASDAQ: SAGE) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.
Medium
Report
Sage Therapeutics, Inc. (NASDAQ: SAGE) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.
11/20
06:43 am
sage
Sage Therapeutics Announces Topline Results from the Phase 2 DIMENSION Study of Dalzanemdor (SAGE-718) in the Treatment of Cognitive Impairment Associated with Huntington's Disease [Yahoo! Finance]
High
Report
Sage Therapeutics Announces Topline Results from the Phase 2 DIMENSION Study of Dalzanemdor (SAGE-718) in the Treatment of Cognitive Impairment Associated with Huntington's Disease [Yahoo! Finance]
11/20
06:30 am
sage
Sage Therapeutics Announces Topline Results from the Phase 2 DIMENSION Study of Dalzanemdor (SAGE-718) in the Treatment of Cognitive Impairment Associated with Huntington’s Disease
Medium
Report
Sage Therapeutics Announces Topline Results from the Phase 2 DIMENSION Study of Dalzanemdor (SAGE-718) in the Treatment of Cognitive Impairment Associated with Huntington’s Disease
10/31
11:05 pm
sage
Sage Therapeutics, Inc. (NASDAQ: SAGE) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Medium
Report
Sage Therapeutics, Inc. (NASDAQ: SAGE) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
10/30
03:35 pm
sage
Sage Therapeutics, Inc. (NASDAQ: SAGE) had its price target lowered by analysts at Scotiabank from $17.00 to $14.00. They now have a "sector outperform" rating on the stock.
Low
Report
Sage Therapeutics, Inc. (NASDAQ: SAGE) had its price target lowered by analysts at Scotiabank from $17.00 to $14.00. They now have a "sector outperform" rating on the stock.
10/30
01:03 pm
sage
Sage Therapeutics, Inc. (NASDAQ: SAGE) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $26.00 price target on the stock, down previously from $52.00.
Medium
Report
Sage Therapeutics, Inc. (NASDAQ: SAGE) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $26.00 price target on the stock, down previously from $52.00.
10/30
12:21 pm
sage
Sage Therapeutics, Inc. (NASDAQ: SAGE) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $9.00 to $8.00. They now have a "market perform" rating on the stock.
Medium
Report
Sage Therapeutics, Inc. (NASDAQ: SAGE) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $9.00 to $8.00. They now have a "market perform" rating on the stock.
10/30
11:37 am
sage
Sage Therapeutics, Inc. (NASDAQ: SAGE) had its price target lowered by analysts at Truist Financial Co. from $13.00 to $8.00. They now have a "hold" rating on the stock.
Medium
Report
Sage Therapeutics, Inc. (NASDAQ: SAGE) had its price target lowered by analysts at Truist Financial Co. from $13.00 to $8.00. They now have a "hold" rating on the stock.
10/30
10:08 am
sage
Sage Therapeutics, Inc. (NASDAQ: SAGE) had its price target lowered by analysts at HC Wainwright from $25.00 to $14.00. They now have a "neutral" rating on the stock.
High
Report
Sage Therapeutics, Inc. (NASDAQ: SAGE) had its price target lowered by analysts at HC Wainwright from $25.00 to $14.00. They now have a "neutral" rating on the stock.
10/30
08:00 am
sage
Sage Therapeutics, Inc. (NASDAQ: SAGE) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.
High
Report
Sage Therapeutics, Inc. (NASDAQ: SAGE) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.
10/29
04:05 pm
sage
Sage Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Pipeline and Business Updates
High
Report
Sage Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Pipeline and Business Updates
10/28
04:30 pm
sage
Levi & Korsinsky Reminds Sage Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 28, 2024 – SAGE
Low
Report
Levi & Korsinsky Reminds Sage Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 28, 2024 – SAGE
10/28
04:00 pm
sage
SAGE SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Sage Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
Low
Report
SAGE SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Sage Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
10/28
12:30 pm
sage
Contact Levi & Korsinsky by October 28, 2024 Deadline to Join Class Action Against Sage Therapeutics, Inc. (SAGE)
Low
Report
Contact Levi & Korsinsky by October 28, 2024 Deadline to Join Class Action Against Sage Therapeutics, Inc. (SAGE)
10/28
10:15 am
sage
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 28, 2024 in Sage Therapeutics Lawsuit - SAGE
Low
Report
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 28, 2024 in Sage Therapeutics Lawsuit - SAGE